Ocular Therapeutix OCUL Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 87.2%-3.4pp | 87.3%-3.8pp | 88.9%-1.7pp | 89.4%-1.4pp | 90.7%-0.3pp | |
| Operating margin | -575.4%-233pp | -519.8%-250pp | -449.7%-220pp | -402.6%-215pp | -342.2%-189pp | |
| Net margin | -558.2%-235pp | -511.9%-208pp | -447.6%-164pp | -382.5%-156pp | -323.1%-130pp | |
| Returns | ||||||
| Return on equity | -68.6%-11.4pp | -54.9%+40.4pp | -81.8%+15.1pp | -63.4%+9.3pp | -57.2%-2.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×-0.1× | 0.1×-0.1× | 0.1×-0.1× | 0.1×-0.1× | |
| Liquidity | ||||||
| Current ratio | 14.8×+4.6× | 15.4×+4.7× | 7.9×-5.2× | 10.1×-6.5× | 10.2×-11.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.2× | 0.1×-0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.1× | |
| Per Share | ||||||
| Book value per share | $2.60+65.3% | $3.49+75.4% | $1.40-33.4% | $1.77-22.2% | $1.57-49.2% | |
| Valuation | ||||||
| Market capitalization | $1.84B+58.2% | $2.59B+92.6% | $2.03B+41.0% | $1.45B+60.4% | $1.17B-3.0% | |
| Price / sales | 35.4×+15.9× | 49.8×+28.7× | 36.5×+13.0× | 25.6×+10.8× | 19.5×-0.5× | |
| Price / book | 3.2×-1.2× | 4×-0.3× | 7.9×+3.8× | 4.7×+2.3× | 4.4×+1.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ocular Therapeutix's profit margins?
- Ocular Therapeutix (OCUL) runs a 87.2% gross margin and a -575.4% operating margin, with a -558.2% net margin.
- Where do Ocular Therapeutix's ratios come from?
- Every ratio is computed from Ocular Therapeutix's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
